Publications by authors named "Johanna Anna Kremer Hovinga"
Introduction: The collected evidence on thrombophilia guidelines is scarce and data about their impact on clinical decisions are unknown. We aimed to investigate the adherence to thrombophilia testing guidelines, its therapeutic impact in patients with guideline-adherent and non-adherent testing and identify the patients' clinical characteristics mostly associated with treatment decisions.
Materials And Methods: We conducted a single-center cross-sectional study of patients referred for thrombophilia testing at the outpatient clinic of a tertiary hospital between 01/2010-10/2020.
Article Synopsis
- Severe COVID-19 can increase von Willebrand factor levels and decrease ADAMTS13 activity, raising the risk of acute thrombotic thrombocytopenic purpura (TTP), especially during inflammation.
- A survey of 122 patients with hereditary TTP found that 70.5% participated, with most vaccinated; however, some faced health issues like ischemic events and myocarditis following vaccination.
- The findings suggest that the risk of acute hTTP episodes is higher with COVID-19 infection than with vaccination, indicating that hTTP patients can safely get vaccinated against SARS-CoV-2.
Article Synopsis
- - The study investigated how well physicians follow evidence-based guidelines for preventing recurrent venous thromboembolism (VTE) in a large group of patients, finding an adherence rate of only 36.1%.
- - Factors influencing adherence included patient age over 50, male sex, and certain clinical characteristics like unprovoked VTE and multiple incidents, but non-adherence was not linked to higher mortality or costs.
- - The research emphasizes the necessity of improving the implementation of evidence-based guidelines in clinical practice, as a low adherence rate could impact patient care quality.
Thrombophilia Impact on Treatment Decisions, Subsequent Venous or Arterial Thrombosis and Pregnancy-Related Morbidity: A Retrospective Single-Center Cohort Study.
J Clin Med
July 2022
Article Synopsis
- - Thrombophilia testing's role in treatment decisions is unclear, leading to ongoing debates about its clinical usefulness.
- - A study involving 3550 patients at Bern University Hospital revealed that about 34% had thrombophilia, with only a small percentage influencing anticoagulation decisions.
- - Those with high-risk thrombophilia faced greater risks of venous thromboembolic events and pregnancy-related issues, highlighting limited benefits of testing in guiding treatments.
Little is known about long-term survival after the initial treatment of venous thromboembolism (VTE). In a prospective cohort study, we aimed to assess the long-term mortality and key predictor variables relating to disease severity, treatment intensity, and comorbidities. Between 1988 and 2018, 6,243 consecutive patients with VTE from a University outpatient unit were prospectively included and followed until December 2019; clinical characteristics, measures of disease severity, and treatment details were recorded.
View Article and Find Full Text PDFThe treatment of patients with acquired hemophilia is challenging due to life-threatening hemorrhages, delayed response, and adverse effects to immunosuppressive agents. Even though immunoadsorption (IA) rapidly removes autoantibodies against factor VIII, this intervention's effectiveness is still a matter of debate. We aimed to study important outcomes of IA as adjunctive treatment in patients with acquired hemophilia.
View Article and Find Full Text PDF